The aim of the study was to examine the prevalence of EGFR-activating mutations and ALK rearrangements among patients with NSCLC and to evaluate the associations between EGFR mutations and clinicopathological characteristics. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.